1402830-75-4

Usage

Uses

Used in Pharmaceutical Industry:
3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone is used as a pharmaceutical compound for its potential therapeutic effects. The compound may exhibit biological activities that can be harnessed for the development of new drugs targeting various diseases and conditions. Its specific application reason is based on its chemical structure, which may interact with biological targets such as enzymes, receptors, or other cellular components, leading to desired pharmacological effects.
Used in Chemical Research:
In the field of chemical research, 3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone serves as a valuable compound for studying its chemical properties, reactivity, and potential use in the synthesis of other complex molecules. The compound's unique structure may provide insights into new reaction mechanisms, catalysts, or methodologies in organic chemistry.
Used in Material Science:
3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone may also find applications in material science, particularly in the development of new materials with specific optical, electronic, or mechanical properties. The compound's structure could be utilized in the design of novel materials for various applications, such as sensors, displays, or energy storage devices, based on its potential interactions with light or other stimuli.

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 313273-62-0 3-acetyl-4-phenyl-1,2-dihydroquinolin-2-one 
• 2835-77-0 (2-aminophenyl)(phenyl)methanone 

Relevant academic research and scientific papers

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small organic molecules (dubbed "fully small-molecule-induced synthetic lethality"). We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncology. We discovered a dihydroquinolone pyrazoline-based molecule (35d) that disrupts the RAD51-BRCA2 protein-protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line. In addition, it synergizes with olaparib (a PARPi) to trigger synthetic lethality. This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.

An Expedient Approach for the Synthesis of Bioactive Pyrazole, Isoxazole and Benzodiazepine-Substituted Quinolin-2(1H)-one Derivatives

A sequence of functionalized pyrazole, isoxazole and benzodiazepine-substituted quinolone derivatives were synthesized in good yield starting from readily available starting precursors. These approaches lead to the synthesis of hitherto unknown compounds with a varied substitution pattern by both conventional and microwave-assisted method. A good number of analogues were evaluated for their in vitro cytotoxicity against human cervical and colon cancer cell lines by MTT protocol. Almost all the selected compounds showed remarkable cytotoxic activities. Among them, compound 4g and 4i emerged as the most promising scaffolds. These scaffolds will be used for further molecular level studies.